Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II linsitinib in relapsed/refractory Ewing sarcoma
2012-000616-28Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of linsitinib in Ewing sarcoma and Ewing sarcoma of bone, sponsored by University of Oxford. Primary endpoints: Tumor biomarker and PET scan response and Progression-free survival (Bayesian primary endpoint). Started Mar 2013; status: completed.
02
Drugs
linsitinib
03
Conditions
Ewing sarcomaEwing sarcoma of bone
Beyond the preview
Go deeper on 2012-000616-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000616-28.